TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01430052

Intervention type: DRUG
Group type: OTHER
Intervention: Drug: gemcitabine, S-1
Description: Gemcitabine 1,000mg/㎡ is administered with 30 min intravenous infusion on day 1 and 8 every 3 weeks. S-1 60mg/㎡/day is administered orally for 2 consecutive weeks every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine, S-1, radiotherapy
Description: Gemcitabine 600mg/㎡ is administered with 30 min intravenous infusion on day 1 and 8 every 3 weeks. S-1 60mg/㎡/day is administered orally for 2 consecutive weeks every 3 weeks. Concurrent radiotherapy (a total dose of 50.4Gy) was delivered in 28 fractions.
Study: NCT01858935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ND-L02-s0201 Injection
Description: Single IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ND-L02-s0201 Injection
Description: Single IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ND-L02-s0201 Injection
Description: Single IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ND-L02-s0201 Injection
Description: Single IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ND-L02-s0201 Injection
Description: Single IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ND-L02-s0201 Injection
Description: Single IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ND-L02-s0201 Injection
Description: Single IV infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single IV infusion.
Study: NCT00525655

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-Based Multimedia Intervention
Description: Website designed to offer information and support for adolescents and young adults with FAP, viewed for 30-60 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Questionnaires taking 10-15 minutes to complete.
Study: NCT04267484

Intervention type: DEVICE
Intervention: GPS and travel diary
Description: WP1: GPS tracker for 2 weeks and a daily diary about activity (travel diary).

Intervention type: OTHER
Intervention: e-decision support platform
Description: WP2 and WP3: An e-decision support platform that will foster shared decision making about options to stay safe at home for the older adult.
Study: NCT00666016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRO19622
Description: TRO19622 500 mg once a day before noon meal during 6 weeks
Study: NCT01500681

Intervention type: PROCEDURE
Intervention: Plasma exchange (PLEX)
Description: Regular maintenance PLEX courses, typically 3 procedures monthly
Study: NCT03985969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: elafibranor
Description: Elafibranor 120mg is a coated tablet for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHRONO-INDOCID
Description: CHRONO-INDOCID 75mg is a capsule for bis in die (bid) oral administration
Study: NCT01266187

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: adjuvant surgery + FOLFOX + cetuximab
Description: surgery -\> 4-8 weeks rest -\> 24 weeks FOLFOX + cetuximab

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: perioperative/Folfox + cetuximab
Description: 12 weeks FOLFOX + cetuximab -\> 4 weeks rest -\> surgery~-\> 4-8 weeks rest -\> 12 weeks FOLFOX + cetuximab
Study: NCT00452361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus+MMF or MPS or AZA+Steroid
Description: Corticosteroids will be administered according to local practice, within a daily maintenance dosage range of 2.5 to15 mg for prednisone or prednisolone (2 to 12 mg/day for methylprednisolone) or the alternate day equivalent.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcineurin Inhibitors (either cyclosporine or tacrolimus)+MMF or MPS or AZA+Steroid
Description: The maintenance dose of:~1. MMF will not exceed 1500 mg/day or PMS will not exceed 1080 mg/day~2. AZA will not exceed 75 mg/day~Thereafter, at the discretion of the investigator, MMF/MPS or AZA may be:~1. continued for the entire 104-week period of randomized therapy~2. subsequently discontinued~3. restarted after discontinuation
Study: NCT01670916

Intervention type: DIETARY_SUPPLEMENT
Intervention: probiotics
Description: Capsule with 1 x 10\*\*9 Lactobacillus rhamnosus GG and 1 x 10\*\*8 Bifidobacterium BB12. Two capsules once a day. The capsules are opened and the content is dissolved in mother's milk or water if the baby is given any milk. In tube fed infants, two drops are given in the mouth and the rest in the nasogastric tube.
Study: NCT03116152

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IBI308
Description: IBI308 200mg Intravenous drip every three weeks；

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel/ irinotecan
Description: paclitaxel 175mg/㎡ Intravenous drip every three weeks or irinotecan 180mg/㎡ Intravenous drip every two weeks
Study: NCT02202629

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beverage containing plant based extracts
Description: Intervention involves single exposure, oral consumption of test article following baseline measurements

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beverage containing plant based extracts
Description: Intervention involves single exposure, oral consumption of test article following baseline measurements

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beverage containing plant based extracts
Description: Intervention involves single exposure, oral consumption of test article following baseline measurements
Study: NCT00756262

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus GG or Culturelle
Description: Drug to be administered orally (capsule form). Dose=2 capsules/day for 14 days. Dosage strength= 1x10\^10 bacteria

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Lactobacillus GG or Culturelle
Description: Drug to be administered orally (capsule form). Dose=2 capsules/day for 14 days. Dosage strength= 1x10\^10 bacteria
Study: NCT00473707

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Active management of the third stage of labor
Description: standardized oxytocin infusion (10 units of oxytocin in 500 mL of Ringers lactate over 20 minutes) immediately following delivery of the fetus with gentle cord traction and fundal massage

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Expectant management of the third stage of labor
Description: standardized oxytocin infusion (10 units of oxytocin in 500 mL of Ringers lactate over 20 minutes) in combination with maternal expulsion efforts once spontaneous separation of the placenta had begun

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin and gentle cord traction with fundal massage
Description: standardized oxytocin infusion (10 units of oxytocin in 500 mL of Ringers lactate over 20 minutes) immediately following delivery of the fetus with gentle cord traction and fundal massage

Intervention type: DRUG
Group type: OTHER
Intervention: Oxytocin
Description: standardized oxytocin infusion (10 units of oxytocin in 500 mL of Ringers lactate over 20 minutes) in combination with maternal expulsion efforts once spontaneous separation of the placenta had begun
Study: NCT00671021

Intervention type: OTHER
Intervention: Platelet aggregation
Description: Platelet aggregation TxA2 formation
Study: NCT03783078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (MK-3475)
Description: 200 mg (adult participants) or 2 mg/kg (up to 200 mg; pediatric participants) on Day 1 of each 3-week cycle (Q3W) IV up to 35 administrations (approximately 2 years).
Study: NCT03672890

Intervention type: OTHER
Intervention: Telestroke
Description: Telestroke is an audiovisual communication network that allows for coordination of stroke care from a distant 'hub' site (the telestroke provider location) to an originating 'spoke' site (patient location) in a HIPAA compliant fashion. In TELECAST, inpatient telestroke rounding will be used to oversee the urgent diagnostic stroke evaluation, secondary stroke prevention, health screening \& evaluation, and stroke education in patients admitted with stroke.
Study: NCT03512938

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-surgical periodontal therapy
Description: Patients were motivated and instructed to brush with modified Bass technique and use interdental toothbrushes, dental floss. Each patient underwent quadrant scaling and root planning (SRP) under local anaesthesia over a 4-week period. Root planing (RP) was performed under local anaesthesia (2% lidocaine, epinephrine 1:100.000) and a standard curette set newly sharpened with Arkansas stone was used for each patient.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal therapy
Description: Patients were motivated and instructed to brush with modified Bass technique and use interdental toothbrushes, dental floss. Each patient underwent quadrant scaling and root planning (SRP) under local anaesthesia over a 4-week period. Root planing (RP) was performed under local anaesthesia (2% lidocaine, epinephrine 1:100.000) and a standard curette set newly sharpened with Arkansas stone was used for each patient.
Study: NCT02791763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 to 4 mg tablets of GSK1278863
Description: 7.0 millimeters (mm) round, standard biconvex, white film coated tablets containing 1 mg, 2 mg, or 4 mg of GSK1278863 as active ingredient, to be orally administered once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 to 4 mg tablets of GSK1278863
Description: 7.0 millimeters (mm) round, standard biconvex, white film coated tablets containing 1 mg, 2 mg, or 4 mg of GSK1278863 as active ingredient, to be orally administered once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6 mg GSK1278863 tablet
Description: 9.0 mm round, standard biconvex, white film coated tablets containing 6 mg of GSK1278863 as active ingredient, to be orally administered once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6 mg GSK1278863 tablet
Description: 9.0 mm round, standard biconvex, white film coated tablets containing 6 mg of GSK1278863 as active ingredient, to be orally administered once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epoetin beta pegol
Description: An injectable formulation containing 25 micrograms µg, 50 µg, 75 µg, 100 µg, 150 µg, 200 µg, or 250 µg of epoetin beta pegol per syringe (0.3 mL), supplied as a glass syringe prefilled with epoetin beta pegol solution (clear colorless to pale yellow). Epoetin beta pegol will be subcutaneously administered once every 2 or 4 weeks.
Study: NCT04341519

Intervention type: BEHAVIORAL
Intervention: PTSD
Description: family members: post-traumatic stress disorder (PTSD) related symptoms assessed by Impact of Event Scale Revised (IES-R) at 90 days~Patients:~post-traumatic stress disorder (PTSD) related symptoms assessed by Impact of Event Scale Revised (IES-R) at 90 days

Intervention type: BEHAVIORAL
Intervention: PTSD
Description: family members: post-traumatic stress disorder (PTSD) related symptoms assessed by Impact of Event Scale Revised (IES-R) at 90 days~Patients:~post-traumatic stress disorder (PTSD) related symptoms assessed by Impact of Event Scale Revised (IES-R) at 90 days

Intervention type: BEHAVIORAL
Intervention: Burnout
Description: Symptoms of burnout as assessed by the Maslash Burnout Inventory
Study: NCT01867697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Study: NCT00861952

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuragen
Description: 2-3 drops applied topically 2-3 times per day as needed over a 3 month period
Study: NCT01867697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folinic Acid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folinic Acid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Carbonate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Carbonate
Study: NCT00861952

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Mineral oil
Description: Ad lib use of mineral (scent and color matched to Neuragen) applied topically 2-3 times per day in 2-3 drops per application
Study: NCT01926288

Intervention type: DRUG
Group type: OTHER
Intervention: Entecavir maleate tablets
Study: NCT03736642

Intervention type: BIOLOGICAL
Intervention: blood sampling
Description: 12 ml sample

Intervention type: BIOLOGICAL
Intervention: blood sampling
Description: 12 ml sample
Study: NCT01926288

Intervention type: DRUG
Group type: OTHER
Intervention: Entecavir maleate tablets

Intervention type: DRUG
Group type: OTHER
Intervention: blank Baraclude tablets

Intervention type: DRUG
Group type: OTHER
Intervention: blank Baraclude tablets

Intervention type: DRUG
Group type: OTHER
Intervention: Blank maleate entecavir tablets

Intervention type: DRUG
Group type: OTHER
Intervention: Blank maleate entecavir tablets

Intervention type: DRUG
Group type: OTHER
Intervention: Baraclude tablets
Study: NCT03736642

Intervention type: BIOLOGICAL
Intervention: blood sampling
Description: 12 ml sample

Intervention type: BIOLOGICAL
Intervention: blood sampling
Description: 12 ml sample

Intervention type: OTHER
Intervention: stool sampling
Description: 20 g sample

Intervention type: OTHER
Intervention: stool sampling
Description: 20 g sample

Intervention type: OTHER
Intervention: stool sampling
Description: 20 g sample

Intervention type: OTHER
Intervention: stool sampling
Description: 20 g sample

Intervention type: OTHER
Intervention: urine sampling
Description: 18 ml sample

Intervention type: OTHER
Intervention: urine sampling
Description: 18 ml sample

Intervention type: OTHER
Intervention: urine sampling
Description: 18 ml sample

Intervention type: OTHER
Intervention: urine sampling
Description: 18 ml sample

Intervention type: DIAGNOSTIC_TEST
Intervention: neuropsychological tests
Description: * Go-nogo~* flexibility~* food stroop~* implicit and explicit evaluation~* Child Depression Inventory~* Hamilton Depression Rating Scale

Intervention type: DIAGNOSTIC_TEST
Intervention: neuropsychological tests
Description: * Go-nogo~* flexibility~* food stroop~* implicit and explicit evaluation~* Child Depression Inventory~* Hamilton Depression Rating Scale

Intervention type: DIAGNOSTIC_TEST
Intervention: neuropsychological tests
Description: * Go-nogo~* flexibility~* food stroop~* implicit and explicit evaluation~* Child Depression Inventory~* Hamilton Depression Rating Scale

Intervention type: DIAGNOSTIC_TEST
Intervention: neuropsychological tests
Description: * Go-nogo~* flexibility~* food stroop~* implicit and explicit evaluation~* Child Depression Inventory~* Hamilton Depression Rating Scale
Study: NCT04383418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine nasal spray
Description: dexmedetomidine nasal spray

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine nasal spray
Description: dexmedetomidine nasal spray

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: dexmedetomidine hydrochloride nasal spray blank preparation
Description: dexmedetomidine hydrochloride nasal spray blank preparation
Study: NCT04492332

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: standard lumbar puncture
Description: Subjects underwent a standard lumbar puncture to measure the intracranial pressure (ICP). ICP was measured invasively through lumbar space in the morning.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: standard lumbar puncture
Description: Subjects underwent a standard lumbar puncture to measure the intracranial pressure (ICP). ICP was measured invasively through lumbar space in the morning.

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: standard lumbar puncture
Description: Subjects underwent a standard lumbar puncture to measure the intracranial pressure (ICP). ICP was measured invasively through lumbar space in the morning.

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: standard lumbar puncture
Description: Subjects underwent a standard lumbar puncture to measure the intracranial pressure (ICP). ICP was measured invasively through lumbar space in the morning.
Study: NCT04522830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTL-TML-COVID
Description: Sublingual dosing of BTL-TML-COVID on days 1 and 2 - Day 1 - 1 drop every 15 minutes for the first hour of initiation of treatment then every hour for the balance of the day until bedtime.~Day 2 - 1 drop every 2-3 hours for a total of 6 times during the day. The parallel group assignment will only be maintained until the completion of a minimum of 48 hours of blinded study drug dosing, at which point all subjects will receive the active treatment.~Day 3 - 1 drop every 15 mins for the first hour of the day, then every hour for the balance of the day until bedtime.~Days 4 through 10 - 1 drop every 3-4 hours for a total of four times during the day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sublingual dosing of matching placebo on days 1 and 2 - Day 1 - 1 drop every 15 minutes for the first hour of initiation of treatment then every hour for the balance of the day until bedtime.~Day 2 - 1 drop every 2-3 hours for a total of 6 times during the day. The parallel group assignment will only be maintained until the completion of a minimum of 48 hours of blinded study drug dosing, at which point all subjects will receive the active treatment.~Day 3 - 1 drop every 15 mins for the first hour of the day, then every hour for the balance of the day until bedtime.~Days 4 through 10 - 1 drop every 3-4 hours for a total of four times during the day.
Study: NCT01781299

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AlloDerm RTU

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SurgiMend PRS
Study: NCT01099449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: calcium gluconate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: calcium gluconate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: magnesium sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: magnesium sulfate
Description: Given IV

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: oxaliplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Study: NCT02267798

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional therapy
Description: The conventional rehabilitation program will consist of physiotherapy sessions (100 min/day) following an individualized approach. The program aims at the restoration of mobility and daily living competence. Specific exercises for the affected upper limb will include, bilateral tasks and facilitation techniques.~The amount of treatment will to be comparable between control and experimental groups in order to avoid possible confounding factors.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: arm training combined with FES
Description: Arm training protocol Training sessions will last for 60 minutes. The Reo Therapy System is robot-assisted therapy; during the session the subject's affected hand is placed on or strapped onto a robotic arm and the subject is instructed to either actively reach predefined reach points, or to be guided while the robotic arm leads the arm towards these reach points.~Functional electrical stimulation protocol Experimental group will receive up to 40 minutes of FES after arm training. The device consists is a stimulator containing 5 electrodes positioned to provide reliable activation of the following muscles: extensor digitatum communis and extensor pollices brevis, flexor pollices longus, flexor digitatum superficialis, and thenar muscles.
Study: NCT03803241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD133+ infusion
Description: Infusion of cells cd133+

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: portal vein embolization
Description: portal vein embolization

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: portal vein embolization
Description: portal vein embolization
Study: NCT02448641

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SB623 Implant (2.5M)
Description: 2.5 million SB623 cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SB623 Implant (5.0M)
Description: 5 million SB623 cells

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham surgery
Study: NCT00770159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: odanacatib
Description: Panel A: MK0822 tablets 25 mg once weekly for 3 weeks. Panel B: MK0822 tablets 50 mg once weekly for 3 weeks. Panel C: MK0822 tablets 100 mg once weekly for 3 weeks. Panel D: MK0822 tablets 5 mg once weekly for 3 weeks. Panel E: MK0822 tablets 100 mg once weekly for 6 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: placebo to MK0822
Description: Panel A: placebo to MK0822 tablets 25 mg once weekly for 3 weeks. Panel B: placebo to MK0822 tablets 50 mg once weekly for 3 weeks. Panel C: placebo to MK0822 tablets 100 mg once weekly for 3 weeks. Panel D: placebo to MK0822 tablets 5 mg once weekly for 3 weeks. Panel E: placebo to MK0822 tablets 100 mg once weekly for 6 weeks.
Study: NCT01926288

Intervention type: DRUG
Group type: OTHER
Intervention: Baraclude tablets
Study: NCT02174822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVP-786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVP-786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVP-786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVP-786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Study: NCT01612806

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PriMatrix
Description: fetal bovine dermal scaffold

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PriMatrix Ag
Description: fetal bovine dermal scaffold with Ag

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: moist wound therapy
Description: standard of care moist wound therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: moist wound therapy
Description: standard of care moist wound therapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: moist wound therapy
Description: standard of care moist wound therapy